Keun-Wook Lee

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu et al. · The Lancet Oncology · 2022 · 712 citations · Full text

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Eric Van Cutsem, Yung‐Jue Bang, Feng-yi Feng et al. · Gastric Cancer · 2014 · 588 citations · Full text

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Miao‐Zhen Qiu, Do‐Youn Oh, Ken Kato et al. · BMJ · 2024 · 195 citations · Full text

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

Daniel V.T. Catenacci, Yoon‐Koo Kang, Haeseong Park et al. · The Lancet Oncology · 2020 · 186 citations

Oncology, Esophageal Cancer, Gastrointestinal Oncology +7

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.

Hyun Cheol Chung, Hendrik‐Tobias Arkenau, Lucjan Wyrwicz et al. · Journal of Clinical Oncology · 2016 · 62 citations

Esophageal Cancer, Immunology, Gastroenterology +17